Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026
Filed with TSE · · 5 pages · English
On 6ix: 6ix.com/news/nxera-pharma-operational-highlights-and-consolidated-results-for-the-third-quarter-2026
In the deck
Story so far
Earlier from Nxera Pharma
- Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets
- Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy
- Introduction of the Executive Officer Performance Stock Option Plan and Issuance of Stock Acquisition Rights Under the Plan
- Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ Across Eight Asia-Pacific Markets
- Nxera Announces Successful Resolution of miniG Patent Infringement Action
Later from Nxera Pharma
- Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
- Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026
Follow Nxera Pharma into a list and get an email when it puts out news.
Follow Nxera Pharma